Oxford Lane Capital Corp vs Roivant Sciences Ltd. Common Shares — how do they compare? Oxford Lane Capital Corp trades at $8.67 (market cap $835.71M), while Roivant Sciences Ltd. Common Shares trades at $34.76 (market cap $24.72B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 29.6× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 28.15% dividend while Roivant Sciences Ltd. Common Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oxford Lane Capital Corp for 49 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| OXLC | ROIV | |
|---|---|---|
Market Cap | $835.71M | $24.72B |
Volume | 1,125,263 | 6,279,442 |
Sector | Financials | Health |
52-Week High | $16.74 | $41.81 |
52-Week Low | $8.15 | $16.04 |
Typical Hold Time | 49 Days | 0 Days |
Enterprise Value | $1.23B | $20.99B |
Dividend Yield | 28.15% | — |
Signals from Pluang's Aura AI — not financial advice
OXLC trades at $8.535, up 0.89% on the day, with a bearish technical signal from moving averages. The stock shows a low P/B of 0.81 and a high net income margin of 100.85% for 2025, but recent earnings misses and a sharp decline in 2026 revenue and net profit to negative figures highlight significant volatility. The company maintains a regular dividend payout of $0.20 monthly, supported by financing activities, but faces challenges from operational cash outflows and negative ROE/ROA.
Outlook is cautious due to earnings instability and bearish technicals, though the dividend yield may attract income seekers. Key risks include sustained operational losses, high interest expenses, and reliance on financing for dividends. Analyst consensus is mixed with 50% buy ratings, indicating divided sentiment on recovery potential amid current headwinds.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →